IRB #

STUDY00018118

Title

A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3011 ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ADVANCED SOLID TUMORS

Principal Investigator

Lara Davis

Study Purpose

The purpose of this research study is to test the safety of different doses of the BA3011 alone and in combination with nivolumab and to find out what effects, good and/or bad effects in individuals with locally advanced or metastatic solid tumor.



Medical Condition(s)

Advanced solid tumor that have failed available standard of care therapy

For expansion:
Sarcoma

Eligibility Criteria

1. Individuals 12 years or older
2. Locally advanced or metastatic solid tumors
3. Adequate organ function
4. Other criteria apply

Age Range

12 - 100

Healthy Volunteers Needed

No

Duration of Participation

The study is planned to last for about 2 years. You will receive the study drug alone in combination with Nivolumab for as long as you and the investigator feel that you are tolerating the study drug and the investigator feels it is in your best interest to continue receiving study drug; you follow directions of the investigator; or if you are able to become pregnant, you do not become pregnant. After you finish treatment, you will have safety follow-up visits to see how you are feeling 3 months from your last dose of study drug. Thereafter, your investigator will continue to watch you for side effects and follow your condition every 3 months by telephone.

Minors Included

Yes

Contact

Knight Clinical Trials Information Line
503-494-1080
trials@ohsu.edu

Sponsor

BioAtla LLC

Recruitment End

12/31/2021

Compensation Provided

No


Go Back